BLearning

PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in PAD treatment

Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at VEITHsymposium 2018.

Jaff, Michael

Jaff, Michael

Dr Michael Jaff is professor of medicine at Harvard Medical School (Boston, USA), and president at Newton Wellesley Hospital Corporation (Newton, USA). He served on the steering committee for the ATTRACT trial, and is currently serving on the BEST-CLI trial

Add comment

Subscribe to receive the very best in medical videos